Drug General Information (ID: DDINFBQJUV)
Drug Name			Fenfluramine		Drug Info		Linagliptin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Cns Stimulants				Dpp4 Inhibitors/Antidiabetic Agents
Structure

Mechanism of Fenfluramine-Linagliptin Interaction (Severity Level: Moderate)
Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Drug Name		Fenfluramine				Linagliptin
Mechanism		Hypoglycemic effects				Hypoglycemic effects
Key Mechanism Factor 1
		Factor Name		Hypoglycemia
		Factor Description		Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
Mechanism Description		Increased risk of hypoglycemia by the combination of Fenfluramine and Linagliptin

Recommended Action
Management		Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.

References
1	Product Information. Didrex (benzphetamine) Pharmacia and Upjohn, Kalamazoo, MI.
2	Product Information. Xenical (orlistat). Roche Laboratories, Nutley, NJ.
3	Product Information. Suprenza (phentermine). Akrimax Pharmaceuticals, Cranford, NJ.